Used in cancer immunotherapy to block the PD-L1 protein, thereby enhancing the immune system's ability to detect and destroy tumor cells. It is primarily applied in the treatment of various solid tumors, including non-small cell lung cancer, by inhibiting immune evasion mechanisms used by cancer cells. This antibody serves as a reference standard in preclinical and clinical studies to evaluate the binding affinity and functional activity of investigational PD-L1 targeting agents.